Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis
- 16 September 2013
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (2) , 189-200
Abstract
Whether the combination of lamivudine (LAM) plus adefovir (ADV) de novo is more effective than entecavir (ETV) monotherapy in patients with HBV‐associated decompensated cirrhosis is still controversial. We searched seven randomized controlled trials that included 411 patients in this meta‐analysis. There are 205 and 206 patients in these two groups separately. The pooled risk ratio (RR) and mean difference (MD) were used to assess the treatment effects. ETV monotherapy significantly improved Child–Turcotte–Pugh (CTP) scores (MD = 0.33, 95%CI [0.21–0.44], P < .00001), and was associated with lower rates of serum creatinine increase compared LAM + ADV combination therapy (RR = 4.76, 95%CI [1.11–20.33], P = .04) at 48 weeks. The reduction of alanine aminotransferase (ALT) levels, HBV DNA levels, the rate of ALT normalization, undetectable HBV DNA, HBV e antigen (HBeAg) loss, HBeAg seroconversion and mortality were similar between the two groups. ETV is more effective than LAM + ADV in improving CTP scores at 48 weeks. Both of the LAM + ADV and ETV had similar efficacy in improving virological and biochemical parameters at 48 weeks of follow‐up. Furthermore, use of these agents in decompensated HBV patients was generally safe and well tolerated at 48 weeks. However, the nephrotoxicity of ADV, and the potential adverse effects of ETV should be considered and monitored during prolonged therapy.Keywords
This publication has 36 references indexed in Scilit:
- Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and AdefovirJournal of Laboratory Physicians, 2012
- 707 LONG-TERM DE-NOVO LAMIVUDINE + ADEFOVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B IS EFFICIENT, BUT HAS NEGATIVE IMPACT ON RENAL/BONE SAFETY IN COMPARISON TO ENTECAVIR MONOTHERAPYJournal of Hepatology, 2011
- De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patientsHepatology International, 2011
- Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver diseaseHepatology, 2010
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatology International, 2008
- Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failureHepatology International, 2008
- Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up studyHepatology International, 2007
- Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis BPharmacoEconomics, 2007
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999